Lyophilization, formulation, and stability

Lyophilization (freeze-drying) is the primary method for producing stable, sterile solid dosage forms of peptides and proteins that are insufficiently stable in aqueous solution. The process removes water by sublimation under reduced pressure, yielding a porous cake that can be reconstituted immediately before use.

Lyophilization comprises three stages:

1. Freezing: The solution is cooled to below its eutectic temperature (for crystalline solutes) or glass-transition temperature of the maximally freeze-concentrated solution (Tg') for amorphous systems. Ice crystals form, concentrating the remaining solution. The rate of freezing affects ice crystal size: rapid freezing produces small crystals and high specific surface area; slow freezing produces large crystals and lower surface area. Crystal size affects both drying rate and cake appearance.

2. Primary drying (sublimation): Chamber pressure is reduced below the vapor pressure of ice (typically 50--200 mTorr), and the shelf temperature is raised to provide the heat of sublimation. Ice sublimes directly to water vapor without passing through a liquid phase. The product temperature must remain below the collapse temperature (Tc) — generally about 2°C above Tg' for amorphous systems — or the cake will collapse, losing porosity and potentially entrapping residual moisture.

3. Secondary drying (desorption): After all ice is removed, the shelf temperature is raised further (often 25--50°C) to desorb bound water from the cake. Residual moisture is typically reduced to <1--2% w/w, depending on the formulation.

The lyophilized cake should be:

• Elegant (uniform, without collapse or melt-back)

• Easily wettable and rapidly reconstitutable

• Stable during storage (minimal physical and chemical change)

• Free of cracks or "puffing" (which can cause vial breakage or dose variability)

Critical quality attributes (CQAs) include cake appearance, reconstitution time, moisture content, and the physical form of excipients (amorphous vs. crystalline).

Buffer challenges during freezing

As water freezes, solutes concentrate in the remaining liquid phase. This can cause:

• Buffer salt crystallization: Dibasic sodium phosphate crystallizes as Na₂HPO₄·7H₂O at low temperature, shifting pH toward the monobasic species. A pH shift of >3 units during freezing has been documented for phosphate-buffered systems.

• Eutectic formation: Some buffer components may form eutectic mixtures that melt at temperatures above the freezing point, potentially causing collapse.

Histidine is increasingly preferred as a buffer for lyophilized peptides because it shows minimal pH shift during freezing.

In the dried state, degradation pathways include:

• Hydrolysis: Requires molecular water above a threshold activity. Below the "water monolayer" coverage (~0.05--0.10 g water/g solid), hydrolysis rates are sharply reduced.

• Deamidation: Non-enzymatic deamidation of asparagine and glutamine residues proceeds slowly in the dry state but is accelerated at elevated residual moisture and temperature.

• Oxidation: Methionine, cysteine, tryptophan, and histidine residues can undergo oxidation, catalyzed by metal ions, light, or peroxide impurities in excipients.

• Aspartate isomerization: Aspartate residues can isomerize to isoaspartate via a cyclic imide intermediate, altering structure and potency.

• Maillard reaction: Reducing sugars (lactose, glucose) can react with primary amines on peptide, forming glycation adducts. This is avoided by using non-reducing sugars (sucrose, trehalose).

The glass-transition temperature (Tg) of the dried formulation determines the storage temperature regime. Below Tg, the cake is a glassy solid with molecular mobility sufficiently restricted to limit degradation. Above Tg, the material becomes a supercooled liquid (rubbery state) in which degradation accelerates.

• Target Tg should be >50°C (and ideally >60°C) to allow storage at controlled room temperature.

• Moisture is a plasticizer: increasing residual moisture lowers Tg by 5--10°C per 1% moisture.

• For refrigerated products (2--8°C), a lower Tg may be acceptable, but cold-chain integrity must still be maintained.

Stability testing under ICH Q5C requires:

• Potency assay: Cell-based or binding assay (or HPLC for small peptides) to measure active concentration

• Purity by HPLC: Reversed-phase and size-exclusion methods to quantify degradation products and aggregates

• Appearance: Visual inspection for clarity, color, and particulates

• pH (after reconstitution, if applicable)

• Moisture content (for lyophilized drug product)

• Reconstitution time (if applicable)

• Subvisible particles: Light obscuration or microflow imaging per USP <787>/<788>

1. Carpenter JF, Pikal MJ, Chang BS, Randolph TW. Rational design of stable lyophilized protein formulations: some practical advice. Pharm Res. 1997;14(8):969--975. https://doi.org/10.1023/a:1012180707283

2. Tang XC, Pikal MJ. Design of freeze-drying processes for pharmaceuticals: practical advice. Pharm Res. 2004;21(2):191--200. https://doi.org/10.1023/b:pham.0000016234.73023.75

3. ICH Harmonised Tripartite Guideline. Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products (Q5C). 1995. https://database.ich.org/sites/default/files/Q5C%20Guideline.pdf

4. USP General Chapter <1151> Pharmaceutical Dosage Forms. USP–NF. Rockville, MD: United States Pharmacopeia; 2026.